112 lines
7.5 KiB
Markdown
112 lines
7.5 KiB
Markdown
---
|
|
type: source
|
|
title: "GLP-1 Managed-Access Operating Systems: How Payers Are Building Infrastructure Beyond Formulary"
|
|
author: "on/healthcare tech (strategy analysis)"
|
|
url: https://www.onhealthcare.tech/p/how-commercial-insurers-self-insured
|
|
date: 2026-01-01
|
|
domain: health
|
|
secondary_domains: []
|
|
format: analysis
|
|
status: unprocessed
|
|
priority: high
|
|
tags: [GLP-1, payer, infrastructure, managed-access, value-based-care, employer-benefits, utilization-management]
|
|
intake_tier: research-task
|
|
---
|
|
|
|
## Content
|
|
|
|
Strategic analysis of how payers, PBMs, and employers are restructuring GLP-1 access as a managed-access operating system rather than a standard formulary decision.
|
|
|
|
**The core argument:**
|
|
Traditional yes/no formulary structure cannot accommodate GLP-1 economics:
|
|
- Eligible population: 36.2 million commercially insured adults
|
|
- Cost: $1,000-$1,200+/month recurring
|
|
- Multiple indications: obesity, T2D, cardiovascular risk (2024), MASH F2-F3 fibrosis (2025), sleep apnea (December 2024)
|
|
- The decision tree: which populations qualify, under what thresholds, through which channels, with what behavioral gates, at what subsidy levels, with what discontinuation rules
|
|
|
|
This requires an operating system, not a formulary.
|
|
|
|
**Payer infrastructure being built (2025-2026):**
|
|
|
|
Evernorth EncircleRx:
|
|
- Manages 9 million enrolled lives
|
|
- 15% cost cap or 3:1 savings guarantee
|
|
- ~$200 million saved since 2024
|
|
- $200 copay cap on Wegovy and Zepbound added 2025
|
|
|
|
Optum Rx Weight Engage:
|
|
- Pairs GLP-1 access with obesity specialist navigation, coaching, lifestyle programs
|
|
|
|
UHC Total Weight Support:
|
|
- Requires coaching engagement (Real Appeal Rx or WeightWatchers) as COVERAGE PREREQUISITE
|
|
- [Note: WeightWatchers bankruptcy creates a gap here — the mandated vendor went bankrupt]
|
|
|
|
**Manufacturer direct-to-employer channels (early 2026):**
|
|
|
|
Eli Lilly Employer Connect (March 5, 2026):
|
|
- $449/dose Zepbound direct to employers (vs. $1,000+ retail)
|
|
- 15+ program administrator partnerships: GoodRx, Teladoc, Calibrate, Form Health, Waltz
|
|
- Bypasses PBMs entirely
|
|
|
|
Novo Nordisk parallel DTE:
|
|
- Waltz Health and 9amHealth partnerships
|
|
- Launched January 1, 2026
|
|
|
|
**Indication expansion creating complexity:**
|
|
- Wegovy: cardiovascular risk reduction (2024)
|
|
- Wegovy: noncirrhotic MASH with F2-F3 fibrosis (2025)
|
|
- Zepbound: moderate-to-severe obstructive sleep apnea (December 2024)
|
|
Each indication requires distinct medical-necessity criteria and cost-offset narratives.
|
|
|
|
**The persistence problem (framing the infrastructure need):**
|
|
Meta-regression data:
|
|
- ~50% discontinuation within one year
|
|
- ~60% weight regain within 12 months of cessation
|
|
- 1-in-12 patients remain on therapy at three years (Prime Therapeutics, cited by Mercer)
|
|
These numbers make the ROI case for managed access infrastructure: without behavioral gates, drug-only GLP-1 coverage is cost without durable benefit.
|
|
|
|
**Infrastructure opportunities identified:**
|
|
- Utilization management infrastructure
|
|
- Outcomes-based contracting frameworks
|
|
- Indication-specific cardiometabolic programs
|
|
- Adherence, tapering, and discontinuation management systems
|
|
- Employer-side financing or subsidy products
|
|
|
|
**Coverage expansion from search data:**
|
|
- 43% of 5,000+ employee firms cover GLP-1s for weight loss (up from 28% in 2024)
|
|
- 34% now require behavioral participation as coverage condition (up from 10%)
|
|
- State mandates emerging: North Dakota first (January 2025), California/Connecticut/West Virginia introducing similar legislation
|
|
- CMS: Medicare Part D coverage beginning January 2027
|
|
|
|
## Agent Notes
|
|
|
|
**Why this matters:** The "managed-access operating system" framing is conceptually important. The previous KB description of GLP-1 economics treated the drug as a standalone product with an adherence problem. This analysis shows that payers are treating the drug + behavioral infrastructure as a SYSTEM — a complex managed product requiring ongoing operational management. This changes the nature of what business opportunities exist.
|
|
|
|
**What surprised me:** The manufacturer direct-to-employer channels (Lilly Employer Connect, Novo/Waltz/9amHealth) launched in early 2026. This is manufacturers BYPASSING PBMs to sell directly to employers. If successful, this represents a structural shift in who controls GLP-1 access architecture. The PBMs (Evernorth, Optum Rx) are building infrastructure to stay relevant; manufacturers are trying to go around them.
|
|
|
|
**What I expected but didn't find:** More detail on which employers are using which vendor. UHC requires Real Appeal Rx or WeightWatchers coaching — but WeightWatchers went bankrupt in May 2025 (three months before this analysis). Does UHC now require the post-bankruptcy "clinical-behavioral hybrid" WeightWatchers? This gap in the record is interesting.
|
|
|
|
**New structural insight — the infrastructure layer is separate from the coaching layer:**
|
|
The previous session identified "behavioral support" as the moat opportunity. This analysis reveals a more complex infrastructure stack:
|
|
1. **Access layer**: PBM formulary, prior auth, utilization management (Evernorth, Optum Rx)
|
|
2. **Behavioral coaching layer**: Omada, Noom, Calibrate, WeightWatchers — where atoms-to-bits moat applies
|
|
3. **Contracting layer**: Outcomes-based contracts, risk-sharing (Evernorth's cost cap)
|
|
4. **Manufacturer direct layer**: Lilly Employer Connect, Novo/Waltz — bypassing traditional channels
|
|
|
|
Each layer has different moat characteristics. The behavioral coaching layer is where atoms-to-bits applies. The access/contracting layer is where PBM scale applies. The manufacturer direct layer is where brand power applies.
|
|
|
|
**KB connections:**
|
|
- [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]] — the managed-access OS is a new configuration that doesn't fit cleanly into the existing four-model framework
|
|
- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — behavioral gates are a new mechanism for risk alignment at the pharmacy benefit level
|
|
|
|
**Extraction hints:**
|
|
- CLAIM: "GLP-1 economics require managed-access operating systems beyond standard formulary — payers are building multi-layer access infrastructure covering eligibility, behavioral gates, indication-specific criteria, and discontinuation management" — confidence: likely
|
|
- CLAIM: "Manufacturer direct-to-employer channels (Lilly Employer Connect March 2026, Novo Nordisk January 2026) represent structural challenge to PBM intermediation in GLP-1 access" — confidence: experimental (too new to confirm durability)
|
|
- UPDATE: The "inflationary through 2035" GLP-1 claim is further complicated by manufacturer DTE channels at $449/dose vs. $1,000 retail — pricing compression may be faster than expected
|
|
|
|
**Context:** on/healthcare.tech is a B2B healthcare strategy newsletter (paywalled). This represents sophisticated market analysis from the payer/employer strategy perspective, not consumer-facing.
|
|
|
|
## Curator Notes
|
|
PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
|
|
WHY ARCHIVED: The "managed-access OS" framing is conceptually new — it positions GLP-1 payer infrastructure as a distinct platform opportunity from behavioral coaching, adding a layer to the claim landscape
|
|
EXTRACTION HINT: Extract the managed-access OS framing as a new claim; separately extract the manufacturer-DTE structural disruption as a second claim — these are two distinct insights from the same source
|